Sweden

4.5researched

On the structural axes that matter, the most open market in Europe: anyone can obtain a pharmacy licence, prescription mail order is legal and normal, and TLV rejected Wegovy from reimbursement in February 2026, leaving a fully cash-pay market that 2.5% of the population is already in.

Population: 10.6m
Currency: SEK
Region: Nordic Europe
Updated: 2026-08-23

The six axes

Five is always better for an operator. Hover a label for the question it answers.

OwnershipLag (2009:366) ended the Apoteket AB monopoly. Läkemedelsverket grants an apotekstillstånd to any applicant judged suitable, no pharmacist requirement for the licence-holder, only for staffing.

Remote prescribingDigital-first clinics, Kry, Min Doktor, Doktor.se, Curevo, Viktenheten, prescribe GLP-1s to new patients. Läkemedelsverket has appealed publicly since December 2023 for on-label prescribing but imposed no ban.

Rx mail orderDomestic distanshandel with Rx medicines is explicitly legal and regulated, tightened on 1 November 2025 so packages must go inside mailboxes or be handed over. And unlike Norway, which flatly bans it, Sweden permits inbound cross-border supply: Tullverket states a private individual may order prescription medicines by post from an EEA pharmacy where an EEA-authorised prescriber wrote the prescription and the quantity is under one year of use. The electronic rail is closed exactly as in Norway, since only Swedish-authorised prescribers may appear in the Nationella läkemedelslistan, but HSLF-FS 2021:75 chapter 7 section 8 lets a Swedish pharmacy dispense an EEA prescription issued in writing. Apomeds and Dokteronline are already running that route into Sweden today, in Swedish, naming Wegovy and Mounjaro.

Advertising roomRx-to-consumer advertising is banned under Läkemedelslagen chapter 12, with industry self-regulation by IGN and NBL, which Läkemedelsverket explicitly says it is not bound by. One GLP-1 case is now known and it carries the largest penalty in the atlas: on 6 December 2024 Läkemedelsverket banned Yazen from advertising prescription weight-loss medicines to the public, specifically adverts referring to GLP-1 analogues, on a vite of SEK 750,000 per breach. Two qualifications matter. No ban against anyone else was found, though the regulator does not publish marketing enforcement, so that is a bounded negative rather than a clean one. And a vite cannot be imposed until the injunction gains legal force, so while the appeal is pending the SEK 750,000 is unenforceable, which is the likeliest reason category behaviour has not changed. Sweden has no Danish-style services-marketing ban; the nearest analogue is narrower and sits in radio- och tv-lagen, covering television, on-demand and video-sharing platforms.

Cash-pay marketTLV rejected Wegovy from högkostnadsskydd on 19 February 2026, citing 675m SEK of non-subsidised private sales in 2025. Novo is appealing; Lilly applied for Mounjaro on 4 August 2026.

Market size261,000 people, 2.5 per cent of the population, filled semaglutide at pharmacy in 2025, up from 0.5 per cent in 2024, and tirzepatide reached 95,000 users in its first full year. Mounjaro is now Sweden’s best-selling medicine. The self-pay pool is roughly SEK 2bn in 2025 on Socialstyrelsen data, 99 per cent patient-paid, annualising toward roughly SEK 3.6bn in 2026. This corrects an earlier figure of SEK 675m, which was TLV’s Wegovy-only number rather than the category total. Norway is nonetheless several times larger per head.

How it works here

Ownership [1][2]

Lag (2009:366) om handel med läkemedel, following Prop. 2008/09:145, re-regulated the market and ended the state monopoly. Läkemedelsverket issues an apotekstillstånd to any applicant judged suitable "med hänsyn till sina personliga och ekonomiska förhållanden". The law requires the pharmacy be staffed by farmaceuter during opening hours and have a designated läkemedelsansvarig, it does not require the permit-holder to be a pharmacist.

A foreign founder can incorporate a Swedish AB and apply directly. That is unusual in Europe and worth weighing against the small population.

Mail order and the November 2025 tightening [1][2]

Distance and e-commerce in medicines is a Läkemedelsverket-regulated channel used by every major chain, Apotek Hjärtat, Kronans Apotek, Apoteket AB, Apotea. New rules effective 1 November 2025 require packages to be placed inside mailboxes or delivery boxes, or handed to the customer, after documented loss and theft. ID checks remain mandatory only for narcotics-classed medicines.

Reimbursement rejected, twice tested [1][2][3]

TLV decided on 19 February 2026 (published 23 February) that Wegovy should not be included in högkostnadsskydd, holding the cost not reasonable relative to benefit and warning of subventionsglidning. It cited 675m SEK of non-subsidised private Wegovy sales in 2025, a useful proxy for the size of the cash market. Novo Nordisk is appealing to Förvaltningsrätten i Stockholm. Eli Lilly applied for Mounjaro obesity subvention on 4 August 2026; the decision is pending.

Curevo prices Wegovy at 1,595–2,724 SEK/month by dose and Mounjaro at roughly 2,000–4,700 SEK. Högkostnadsskydd covers only consultation fees (1,450 SEK annual ceiling in 2026), never the drug.

Who is already there

Name	Model	Price
Yazen	Subscription clinic, never touches the drug, clinical gate before payment. The category leader at roughly 86 per cent of native care-fee revenue.	From SEK 1,495/month
Ayd	The only Swedish operator vertically integrated into a pharmacy licence.	Not established
Velora	Weight-loss native, the only profitable one, 46 brand-named URLs.	Not established
Kry	Digital-first clinic with a weight-loss programme; regionally integrated plus a private tier	n/a
Min Doktor, Doktor.se	Digital-first clinics with licensed physicians	n/a
Curevo / Viktenheten	Private cash-pay GLP-1 telehealth specialists	Wegovy 1,595–2,724 SEK/month
Yazen	Nordic GLP-1-focused startup; €3.1m in 2023 then a €19.5m Series A in November 2024	n/a
Apotek Hjärtat, Kronans Apotek, Apoteket AB, Apotea	Chains running distanshandel e-commerce for Rx medicines	n/a

Routes in, and walls

What works viable

Incorporate a Swedish AB and apply to Läkemedelsverket for an apotekstillstånd, no personal pharmacist qualification needed.
Or skip pharmacy ownership entirely: run a physician-staffed telehealth clinic that e-prescribes into any licensed pharmacy's distanshandel channel. This is the Curevo and Viktenheten model.

What does not blocked

Branded Rx-drug consumer advertising, regardless of ownership structure.
Ignoring the November 2025 delivery-handling rules for shipped medicines.

How to make it work

The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.

build

Incorporate a Swedish AB, take an apotekstillstånd in your own name, and run the clinic and the pharmacy under one roof.

Sweden is the only market of scale in Europe where a non-pharmacist can simply own the pharmacy, and the only one where owning both the prescriber and the dispenser appears lawful. Chapter 2 section 5 of the Swedish rule bars a prescriber controlling a pharmacy, not a pharmacy controlling a prescriber, which is the asymmetry that makes the integrated model work here and not in Norway. Ayd is the only operator that has used it. Sweden also permits inbound cross-border supply, so it can serve as the operating core for other markets rather than a single-country bet.

Incorporate the AB and register as a vårdgivare with IVORegistration is free. Do this before anything else, because the clinical entity is what everything else hangs from.
Apply to Läkemedelsverket for an apotekstillståndNo personal pharmacist qualification is required of the owner. Budget for a qualified läkemedelsansvarig and the premises requirements.
Contract Swedish-licensed prescribers and build to the national prescription channelOnly Swedish-authorised prescribers may appear in the Nationella läkemedelslistan, so the domestic prescriber layer is not optional.
Measure the body, do not ask about itIVO criticised Yazen for photo-based identity checks and dosing by counting clicks. A connected scale is cheap and it is the difference between a supervision file and a clean one.
Take the clinical decision before the moneyYazen does this and it is the only operator in the atlas that does. It makes "you only pay if approved" a true claim.
Keep the molecule off commercial surfacesLäkemedelsverket banned Yazen on a vite of SEK 750,000 per breach and reportedly caught the phrase GLP-1 itself, the satiety mechanism, and even "moderna läkemedel". Editorial naming is a separate question from a priced page.

What kills it

Acquisition cost. Two independent operators converge on roughly 350 to 400 euros of marketing per active patient per year, and the line between profitable and not is marketing at about 60 per cent of gross profit. Yazen sits at 79 to 91 per cent and loses money at SEK 330m of revenue. Velora is profitable at SEK 18.4m. Scale is not the answer here, channel discipline is.

Rough effort

Pharmacy licence and clinic registration inside six months on the published processes. The expensive part is not the licence, it is the twelve months of paid acquisition before retention data exists.

What has happened

2023-12

Läkemedelsverket issues its first public appeal against off-label GLP-1 prescribing.

2025-11-01

Tightened distanshandel delivery rules take effect.

2026-02-19

TLV rejects Wegovy from högkostnadsskydd; Novo appeals.

2026-08-04

Eli Lilly applies to TLV for Mounjaro obesity subvention.

2026-07-15

EU authorises the oral Wegovy pill; no Swedish launch date confirmed.

What we could not establish

Kept visible on purpose. These are the gaps a decision would have to close.

Does any major Swedish provider run a questionnaire-only, no-video GLP-1 initiation flow?
What is the outcome of Novo's TLV appeal and Lilly's Mounjaro application?
Is there any GLP-1-specific IGN or NBL enforcement case in 2025–26?